Chadi welcomes Dr. Andrea Apolo, an internationally recognized leader in bladder cancer research from the National Cancer Institute. Dr. Apolo shares her expertise on recent advancements in urothelial cancer therapy, including key breakthroughs in checkpoint inhibition that have marked a significant turning point in treatment. The conversation delves into optimal sequencing and combination strategies for checkpoint inhibitors, contrasts in treatment approaches between early-stage and late-stage disease, and the evolving landscape of bladder-sparing options. Dr. Apolo also provides an in-depth look at the comprehensive process of designing, executing, and publishing impactful clinical research, highlighted by her latest publication in The New England Journal of Medicine.
Read more about her NEJM trial.
www.nejm.org/doi/abs/10.1056/NEJMoa2401726
Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/
Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
